Patient Summit USA 2016

eyeforpharma 10 - 11 October 2016, Sonesta Philadelphia, USA.
The 13th annual Patient Summit USA 2016 is where patient-driven partnerships with stakeholders actually happen. This is not just a talking shop - be one of 300+ senior pharma executives, regulatory authorities, providers, payers, advocates and patients who plan to deliver sustainable solutions to the patient community.

Patient Centricity ...so what?

  • Streamline cultural change by setting a universal framework for patient centricity
  • Prove ROI-driven patient initiatives and get internal buy-in
  • Hear directly from patients and caregivers and mend their disconnect with the industry
  • Overcome roadblocks to advocacy and adherence with an enhanced focus on access programs
  • Navigate a complex regulatory environment while still promoting your patient initiatives

Turn profit-patient into patient-profit
Transforming your profit-patient model into a patient-profit system is one of the biggest shake-ups in pharma's history.

Many major brands are already in the process of creating and developing a new patient-centric approach, and introducing measures to reward staff against patient-oriented metrics.

What was once an 'if?' has become a 'when and how?'. But changing an engrained mind-set requires a collaborative effort; the more companies that encourage–and in some cases enforce–patient-centricity, the more widespread the buy-in will be.

'Profit' is still a valid talking point - it hasn't become a dirty word. What has changed is that it is now being seen as a natural by-product of putting patients first.

Now that patients are being almost universally regarded as pivotal to the sustained growth of pharma, the question turns back to: how will an inverted model still provide profit for pharma and key stakeholders?

The conference aims to help pharma stakeholders share views, and examine ways to put patients at the centre of evolving pharma business models, without damaging profits. Putting patients first needs to be attractive on both the humanistic and fiscal levels in order for patient centricity to thrive.

World Pharma News readers can benefit from an exclusive discount code, save €200 using World Pharma News unique code WorldPharma200

For further information, please visit:
http://www.eyeforpharma.com/patientusa/

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]